Search is restricted to the following diseases:
Search Results for "EPO" - 31 interactions found in 14 entries.
|
|
|
Interactor1 (Subject) |
|
Interaction type |
Interactor2 (Object) |
additional information |
|---|
|
|
|
|
202
|
| 802 |
EPO
|
|
decreases_activity of
|
neuron death
|
|
| 811 |
EPO
|
|
decreases_activity of
|
Kainic acid
|
on apoptosis
|
|
18413601
|
Amyotrophic lateral sclerosis
|
|
547
|
| 13800 |
EPO
|
|
decreases_activity of
|
abnormal blood-brain barrier function
|
in pilocarpine model
|
| 13801 |
EPO
|
|
decreases_activity of
|
neuron death
|
in pilocarpine model
|
| 13802 |
EPO
|
|
decreases_activity of
|
microglial cell activation
|
in pilocarpine model
|
| 13803 |
EPO
|
|
decreases_activity of
|
abnormal hippocampus granule cell morphology
|
in pilocarpine model
|
| 13804 |
EPO
|
|
decreases_activity of
|
convulsive seizures
|
|
|
18479396
|
Status epilepticus
|
|
1,474
|
| 10391 |
EPO
|
|
decreases_activity of
|
apoptotic process
|
|
| 10392 |
EPO
|
|
decreases_quantity of
|
BCL2L11
|
|
| 10393 |
EPO
|
|
increases_phosphorylation of
|
BCL2L11
|
|
|
19100675
|
Amyotrophic lateral sclerosis
|
|
1,908
|
| 14618 |
EPO
|
|
increases_expression of
|
BCL2L1
|
together with GATA1
|
|
10381501
|
Hematological
|
|
5,910
|
| 55880 |
EPO
|
|
decreases_activity of
|
CEBPA
|
|
|
|
Diabetes mellitus, type II
Insulin resistance
Hemochromatosis, type 1
|
|
6,718
|
| 64875 |
EPO
|
|
increases_phosphorylation of
|
FES
|
|
|
11994747
|
Cancer
|
|
6,775
|
| 65780 |
EPO
|
|
increases_activity of
|
FES
|
in UT-7/EPO cells
|
| 65784 |
EPO
|
|
increases_activity of
|
JAK2
|
in UT-7/EPO cells
|
|
11756159
|
Hematological
|
|
6,900
|
| 68042 |
EPO
|
|
affects_activity of
|
TOR signaling
|
|
| 68043 |
EPO
|
|
decreases_activity of
|
hyperglycemia
|
|
| 68044 |
EPO
|
|
decreases_activity of
|
wound healing
|
|
| 68045 |
EPO
|
|
increases_activity of
|
endothelial cell
|
|
| 68046 |
EPO
|
|
decreases_activity of
|
abnormal mitochondrial physiology
|
|
| 68047 |
EPO
|
|
decreases_activity of
|
response to oxidative stress
|
in Schwann cells
|
| 68048 |
EPO
|
|
decreases_activity of
|
apoptotic process
|
in Schwann cells
|
| 68049 |
EPO
|
|
affects_activity of
|
AMPK
|
|
|
27127460
|
Diabetes mellitus, type II
Insulin resistance
|
|
12,207
|
| 119925 |
DPP4
|
|
affects_activity of
|
EPO
|
via proteolytic cleavage
|
|
32294179
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
13,495
|
| 127177 |
EPO
|
|
affects_activity of
|
Nephropathy, diabetic
|
|
|
25280384
|
Nephropathy, diabetic
|
|
13,628
|
| 128215 |
hypoxia
|
|
increases_expression of
|
EPO
|
|
|
27228995
|
Chronic kidney disease
|
|
13,630
|
| 128218 |
EFNA1
|
|
increases_expression of
|
EPO
|
in HEP-3B cells
|
|
27228995
|
Chronic kidney disease
|
|
15,112
|
| 141611 |
EPO
|
|
increases_activity of
|
erythrocyte differentiation
|
|
| 141612 |
EPO
|
|
interacts (colocalizes) with
|
EPOR
|
|
|
|
Hematological
|
|
15,115
|
| 141626 |
EPO
|
|
increases_phosphorylation of
|
JAK2
|
|
| 141627 |
EPO
|
|
increases_activity of
|
JAK2
|
via phosphorylation
|
|
|
Hematological
|
CIDeRplus